Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. - Wikidata - awgldk - TriplyDB

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

http://www.wikidata.org/entity/Q34179254

about

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Patients' perspectives on taking warfarin: qualitative study in family practice Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation Recurrent venous thromboembolism: what is the risk and how to prevent it Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis Predicting the risk of venous thromboembolism recurrence Chronic thromboembolic pulmonary hypertension: Medical treatment.Duration of anticoagulation for venous thromboembolic events Unresolved issues in anticoagulant therapy Guidelines on oral anticoagulation with warfarin - fourth edition Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations.Current issues in anticoagulation.The role of ximelagatran in the treatment of venous thromboembolism.Thrombosis in small and medium-sized pulmonary arteries in Wegener's granulomatosis: a confocal laser scanning microscopy study.Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review Predictors of venous thromboembolism in patients with advanced common solid cancers Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009)Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol.Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism.Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study.Guidelines on oral anticoagulation (warfarin): third edition--2005 update.Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked Warfarin for refractory chronic cluster headache: a randomized pilot study.CLIA-tested genetic variants on commercial SNP arrays: potential for incidental findings in genome-wide association studies.Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.Optimal duration of anticoagulation after venous thromboembolism.Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.Life-threatening aortic thrombosis in a trauma patient homozygous for factor V Leiden mutation: Case report

P2860

Q24194466-0B3FB470-32A8-442A-BF90-A0C6E1B4ECED Q24632951-D821E92A-62D4-4D28-AFD3-0533C341AED2 Q24633053-298A989C-FD2A-4D56-82F6-7989B2DC1968 Q24798132-E470E051-F971-4178-AB06-5BD8F01A3D1B Q24803323-8B93C2F1-0953-49A7-B030-A79C571413FC Q25257138-BBAB5DDA-F713-44D9-A56B-E482709071CF Q26749273-86E44D99-F802-44A7-A7C3-F08F472F0A10 Q26825608-2923B6BB-0D41-44FE-8101-7BC274313611 Q26826847-28378826-4E1A-434D-AE47-21CA5FA90AA8 Q26828750-8BA7BDE5-AEFF-49DB-B0E8-DA3B9DA4D0D4 Q26865059-9A98E574-B6ED-46C1-9788-188D3A268898 Q27687768-29848699-143C-4101-8532-622566AB800E Q28081375-B568C8C4-7EE6-4B64-BFC0-DB87098064AF Q28196778-F6AE4A87-CB17-45D9-BAFF-151DED718186 Q28240666-E7A96F60-80DE-490E-A5AE-EAF119A96F60 Q28243221-CD7568D4-23F7-45BC-ABD4-5ECEE2F15321 Q30251792-D84F8A45-A6BF-4678-8441-583B4D00DE5C Q33365707-C0846EE0-9FF8-432F-AFC5-4F83DAF1E71B Q33369274-D368B0CD-3CF1-4919-8805-C503C1F68460 Q33790855-42E0E780-6124-4984-9481-BE1165D8AE7F Q33795571-EA3013CA-9A8C-4F02-BFCE-9DB7C4E8D37E Q33810510-586F33BB-3CD7-4093-B92D-D90F8AE656F7 Q33821311-6BFF3704-8E96-4BD8-85B1-481B534EF804 Q33910755-56807FE1-0102-4755-B597-9B5AD827B46A Q34085379-7E3CB99C-441B-450D-A867-96EA66969F81 Q34167655-D441FBC7-E32D-4B34-BCB9-24D9D9121FDE Q34252907-6F3E0B26-2705-477B-A4BD-4DA13AE09099 Q34284224-29C20B37-FBF3-4E88-9DEB-C8DF4FDDF2A2 Q34286102-52FA4096-DCF4-4CCE-881D-6FB7BF122B04 Q34340059-9502BADC-2E45-48D4-8C9F-0BF451453E2E Q34362277-B7CCCE3F-077A-43C8-91DF-CF080ED40974 Q34410222-381ED1B1-F566-4493-A1C9-0F4F663D13A9 Q34484090-95A8593E-5AB8-4132-AECC-6FE2A0478044 Q34623435-3B7012D8-30FB-4559-BFDF-7880CE0F5772 Q34660438-42DD984B-B90B-4FF4-96D2-3D3938CB78E2 Q34669217-1CDBAABE-DDB7-4E2A-99F3-775C61075B5A Q34742633-0CAD0F73-BA52-4C2F-8023-A99CD9BB3FAC Q34781477-4CF230DA-D12F-4C17-877B-31E847700B09 Q34787240-BBBE329E-BC80-47AD-AC65-F0073B1E9F30 Q35037469-3EE07703-4121-4558-ABBC-1EFC707F2F0A

P2860

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

http://www.wikidata.org/entity/Q34179254

description

2003 nî lūn-bûn

@nan

2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@ast

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@en

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@nl

type

label

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@ast

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@en

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@nl

prefLabel

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@ast

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@en

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@nl

P1433

Q34179254-9F9C9A73-FF7C-4C56-8190-5EBFC39E814B

P1476

Q34179254-6EB6C46C-C9A5-4EA3-A8D3-165F365C08AC

P2093

Q34179254-1AF3F66C-3855-4F73-AB5C-DF8911021A48

Q34179254-3A6468F4-EB34-40B9-8C80-E52227DBB61E

Q34179254-518B7FF2-9409-4958-A6D6-AD7C0B0A2A0A

Q34179254-6528D75F-AA43-48A1-B97B-E650611256D3

Q34179254-6E5EE370-47BF-490E-BE2C-6D4A8AA494D6

Q34179254-941DDEFC-F591-4587-AF01-08286F3FE561

Q34179254-99FC2422-FB5D-49E9-8C50-45B208270AC2

Q34179254-A135FA9F-CC2C-4223-8DBD-7AC376E5AFFA

Q34179254-A7214BA1-6700-44CD-B0EF-1BD0CBB0D55A

Q34179254-A7C63146-8053-4D2B-808F-2982B606EA46

P304

Q34179254-EA9BE35C-254A-4366-8D67-28075A4B9008

P31

Q34179254-51B238B5-809B-47C2-B470-D80C4547A08A

P356

Q34179254-88D4286D-9C89-467B-88A4-7C81ABFA7C8A

P407

Q34179254-CF6C18F9-40A8-433A-8DFB-38F6D78A62B6

P433

Q34179254-59FF01E1-8ED6-4CF2-AA17-B82FB8F476A8

P478

Q34179254-8B1D5196-DDFD-4A97-9305-5B746A38871D

P50

Q34179254-0C47CFE4-98C4-4721-B1EB-A97252CB670E

P577

Q34179254-29898215-827D-40DB-9662-149BE16879C2

P698

Q34179254-3850D15C-0D57-47F2-A958-987CFAE168FC

P356

P1433

The New England Journal of Medicine

P1476

Long-term, low-intensity warfa ...... urrent venous thromboembolism.

@en

P2093

Bruce A Schwartz

http://www.w3.org/2001/XMLSchema#string

C Gregory Elliott

http://www.w3.org/2001/XMLSchema#string

Charles S Eby

http://www.w3.org/2001/XMLSchema#string

Craig M Kessler

http://www.w3.org/2001/XMLSchema#string

Ellie Danielson

http://www.w3.org/2001/XMLSchema#string

Henri Bounameaux

http://www.w3.org/2001/XMLSchema#string

Joseph P Miletich

http://www.w3.org/2001/XMLSchema#string

Kenneth A Bauer

http://www.w3.org/2001/XMLSchema#string

PREVENT Investigators

http://www.w3.org/2001/XMLSchema#string

Paul M Ridker

http://www.w3.org/2001/XMLSchema#string

P304

1425-1434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA035029

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

348

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12601075

http://www.w3.org/2001/XMLSchema#string